FX.co ★ GSK To Appeal Delaware State Court Ruling On Zantac Litigation

GSK plc (GSK, GSK.L) announced on Monday its intention to appeal a recent ruling by the Delaware State Court regarding the Zantac (ranitidine) litigation. The company expressed disagreement with the court's decision, noting its contradiction to a December 2022 ruling by the Federal Court's Multidistrict Litigation, which under the same legal standard, dismissed all claims relating to five types of cancer.

After comprehensive analysis of 16 epidemiological studies on human data concerning ranitidine use, the scientific consensus remains that there is no consistent or reliable evidence linking ranitidine to an increased risk of cancer, GSK emphasized.

GSK reaffirmed its commitment to vigorously defend against all claims, prioritizing the best interests of its shareholders. In addition to seeking an immediate appeal to the Delaware Supreme Court, the company plans to file motions for dismissal based on further defenses, severance of cases, and proof-of-use by claimants. Concurrently, GSK will proceed to individual case trials.

The company clarified that its capital allocation priorities remain unchanged and that the ruling does not affect its growth investment plans.